Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27

Cell Rep. 2022 Oct 18;41(3):111490. doi: 10.1016/j.celrep.2022.111490.

Abstract

Interleukin-27 (IL-27) uniquely assembles p28 and EBI3 subunits to a heterodimeric cytokine that signals via IL-27Rα and gp130. To provide the structural framework for receptor activation by IL-27 and its emerging therapeutic targeting, we report here crystal structures of mouse IL-27 in complex with IL-27Rα and of human IL-27 in complex with SRF388, a monoclonal antibody undergoing clinical trials with oncology indications. One face of the helical p28 subunit interacts with EBI3, while the opposite face nestles into the interdomain elbow of IL-27Rα to juxtapose IL-27Rα to EBI3. This orients IL-27Rα for paired signaling with gp130, which only uses its immunoglobulin domain to bind to IL-27. Such a signaling complex is distinct from those mediated by IL-12 and IL-23. The SRF388 binding epitope on IL-27 overlaps with the IL-27Rα interaction site explaining its potent antagonistic properties. Collectively, our findings will facilitate the mechanistic interrogation, engineering, and therapeutic targeting of IL-27.

Keywords: CP: Immunology; IL-12 family; IL-27; IL-27Rα; antagonism; cytokine-antibody complex; cytokine-receptor complex; gp130; immunotherapy; signaling; therapeutic antibody.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Cytokine Receptor gp130 / metabolism
  • Cytokines
  • Epitopes
  • Humans
  • Interleukin-12
  • Interleukin-23
  • Interleukin-27*
  • Mice
  • Receptors, Cytokine / metabolism

Substances

  • Interleukin-27
  • Cytokine Receptor gp130
  • Receptors, Cytokine
  • Interleukin-12
  • Cytokines
  • Antibodies, Monoclonal
  • Epitopes
  • Interleukin-23